Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy

Efficacy and safety of switching to travoprost/timolol fixed-combination therapy from latanoprost monotherapy

“…However, the findings of our study did not reveal any significant differences between latanoprost monotherapy and TTFC therapy in terms of corneal disorders. Kitazawa et al [22] found no differences between BAC-containing TTFC and non-BACcontaining TTFC in terms of corneal disorders, which is consistent with the results of our study. However, it is possible that the lack of differences found in our study was due to the fact that our patients presented with either none or only mild corneal disorders before being switched to TTFC therapy.…”

Phase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension

“…The baseline visit was scheduled at least 4–27 days after the screening visit according to the required drug washout duration for discontinued IOP-lowering drugs (β-blockers and prostaglandin analogs, >27 days; α and αβ agonists, >13 days; miotics and carbonic anhydrase inhibitors, >4 days); when multiple medications were used (fixed or unfixed combinations), a longer washout period was used. These washout periods were similar to durations described in previous studies 26,27. Baseline ophthalmic assessments (IOP, best-corrected visual acuity, visual field test, slit-lamp examination, gonioscopy, ophthalmoscopy), physiologic assessments (resting blood pressure, pulse rate), and laboratory tests were performed at 9 am for the screening or baseline visit before administration of the investigational drug; IOP, blood pressure, and pulse were also assessed at 11 am, 2 hours post instillation.…”

Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice

“…BAK-free formulations have been demonstrated to be noninferior in reducing IOP as the same medications preserved with BAK [73,[81][82][83][84][85][86][87]. Currently, several BAK-free preserved and preservative-free formulations of ocular hypotensive monotherapies and fixed-dose combinations (e.g., tafluprost, travoprost, bimatoprost, brimonidine, timolol, fixed-combination travoprost/timolol, fixed-combination dorzolamide/timolol) are commercially available.…”